IceCure Medical (ICCM) wins new 180-day window to meet Nasdaq $1 bid

Rhea-AI Filing Summary

IceCure Medical reports that Nasdaq has granted the Company an additional 180-day period, until November 9, 2026, to regain compliance with the exchange’s $1.00 minimum bid price requirement for its ordinary shares.

The extension follows a prior 180-day window that ended on May 11, 2026, during which IceCure did not regain compliance. The Company has indicated it intends to cure the deficiency and may, if needed, implement a reverse share split. If the closing bid price is at least $1.00 for a minimum of 10 consecutive business days before November 9, 2026, Nasdaq will deem the Company compliant, though Nasdaq can require up to 20 days.

The notice has no immediate effect on the listing or trading of IceCure’s ordinary shares, which continue to trade on the Nasdaq Capital Market under the ticker ICCM.

Insights

Equity markets and listing standards analyst

Nasdaq grants IceCure more time, but bid-price risk remains.

Nasdaq has given IceCure Medical a second 180-day period, until November 9, 2026, to restore its share price to at least $1.00. This follows an initial 180-day window that ended on May 11, 2026 without the Company regaining compliance.

The Company met all other Nasdaq Capital Market listing criteria, so the only deficiency involves the minimum bid price rule. IceCure has notified Nasdaq that it plans to cure the issue and may, if necessary, execute a reverse share split, which mechanically boosts the per-share price without changing overall market value.

To regain compliance, the closing bid must be at least $1.00 for 10 consecutive business days before November 9, 2026, although Nasdaq can extend this requirement up to 20 days. Until then, ICCM shares continue trading normally, but future disclosures will clarify whether price levels or any reverse split achieve sustained compliance.

Key Figures

New compliance period length: 180 days Minimum bid price requirement: $1.00 per share New compliance deadline: November 9, 2026 +4 more

7 metrics

New compliance period length 180 days Additional Nasdaq bid-price compliance window ending November 9, 2026

Minimum bid price requirement $1.00 per share Nasdaq Capital Market continued listing standard for IceCure ordinary shares

New compliance deadline November 9, 2026 End of second 180-day period to regain $1.00 minimum bid

Initial compliance deadline May 11, 2026 End of first 180-day period after November 12, 2025 notice

Required trading streak 10 consecutive business days Minimum time ICCM must close at or above $1.00 to regain compliance

Possible extended streak Up to 20 business days Nasdaq may require a longer period of $1.00-plus closing bids

Initial noncompliance lookback 30 consecutive business days Period over which ICCM traded below $1.00 before November 12, 2025 notice

Key Terms

minimum bid price rule, reverse share split, Nasdaq Capital Market, forward-looking statements, +1 more

5 terms

minimum bid price rule regulatory

"to regain compliance with Nasdaq’s minimum bid price rule."

A minimum bid price rule is a stock market requirement that a listed company's share must trade above a set minimum price over a specified period to remain listed on an exchange. It matters to investors because falling below that threshold can trigger warnings, potential delisting, and reduced liquidity—similar to a student needing a passing grade to stay enrolled—making the shares harder to buy, sell, or value accurately.

reverse share split financial

"its intention to cure the deficiency ... by effecting a reverse share split."

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

Nasdaq Capital Market market

"initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

forward-looking statements regulatory

"This press release contains forward-looking statements within the meaning of the “safe harbor” provisions"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

market value of publicly held shares financial

"based on the Company meeting the continued listing requirement for market value of publicly held shares"

The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 05/13/2026 - 05:00 PM Learn about SEC filing dates

FAQ

What did IceCure Medical (ICCM) announce regarding its Nasdaq listing?

IceCure Medical announced that Nasdaq granted a second 180-day period, until November 9, 2026, to regain compliance with the $1.00 minimum bid price rule. The shares remain listed and trading on the Nasdaq Capital Market under the symbol ICCM during this extension.

Why is IceCure Medical (ICCM) out of compliance with Nasdaq rules?

Nasdaq notified IceCure on November 12, 2025 that its ordinary shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days. IceCure did not restore its bid price during the initial 180-day window ending May 11, 2026.

How can IceCure Medical regain compliance with Nasdaq’s minimum bid price?

IceCure can regain compliance if its ordinary shares close at or above $1.00 per share for at least 10 consecutive business days before November 9, 2026. Nasdaq may, at its discretion, require up to 20 consecutive business days of $1.00-or-higher closing bids.

Is IceCure Medical planning a reverse share split to meet Nasdaq rules?

IceCure stated in writing to Nasdaq that it intends to cure the bid-price deficiency and, if necessary, may effect a reverse share split. A reverse split would increase the per-share price by consolidating shares without changing total market capitalization.

Does the Nasdaq notice immediately affect trading of IceCure (ICCM) shares?

The current Nasdaq notification has no immediate effect on trading or listing. IceCure’s ordinary shares continue to trade on the Nasdaq Capital Market under the ticker ICCM while the Company works to regain compliance during the additional 180-day period.

What deadlines has Nasdaq set for IceCure Medical’s bid-price compliance?

Nasdaq initially gave IceCure until May 11, 2026 to restore its bid price to at least $1.00. After the Company requested more time, Nasdaq granted an additional 180-day compliance period ending November 9, 2026, keeping the same $1.00 bid-price condition.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: May 2026 (Report No. 5)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F                  ☐ Form 40-F

CONTENTS

On May 13, 2026, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement”, a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K.

This Report on Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-290046 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit No.
99.1		Press release dated May 13, 2026, titled “IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement.”

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.
Date: May 13, 2026	By:	/s/ Eyal Shamir
		Name	Eyal Shamir
		Title:	Chief Executive Officer

2 

Exhibit 99.1

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares

CAESAREA, Israel, May 13, 2026 -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until November 9, 2026 to regain compliance with Nasdaq’s minimum bid price rule.

Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse share split.

In a notification letter dated November 12, 2025, Nasdaq had first informed the Company that, based on the previous 30 consecutive business days, the Company’s ordinary shares no longer met the minimum $1.00 bid price per share requirement and in accordance with Nasdaq’s Listing Rules, the Company was provided 180 calendar days, or until May 11, 2026, to regain compliance. The Company did not regain compliance with the minimum $1.00 bid price per share requirement during the first 180-calendar-day compliance period and submitted a written request to the Nasdaq’s staff to afford it an additional 180-day compliance period to cure the deficiency, which it was granted in a notification letter dated May 12, 2026.

If at any time before November 9, 2026, the closing bid price of the Company’s ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. However, Nasdaq may, in its discretion, require the Company’s ordinary shares to maintain a bid price of at least $1.00 for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

This current notification from Nasdaq has no immediate effect on the listing or trading of the Company’s ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol “ICCM.”

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. 

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, IceCure is using forward-looking statements when it discusses regaining compliance with Nasdaq’s continued listing requirements, and the timing and effect thereof as well as potentially effecting a reverse share split. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on IceCure’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in IceCure’s Annual Report on Form 20-F filed with the SEC on March 17, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, IceCure disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:

Email: investors@icecure-medical.com

Michael Polyviou

Phone: 732-232-6914

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE DATED MAY 13, 2026, TITLED "ICECURE GRANTED 180-DAY EXTENSION BY N 8.1 KB